The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia

Haematologica

Volumn 96, Issue 10, 2011, Pages 1560-1564

  Rocha, Andreia Maria Camargos ^a   Souza, Cláudia ^a   Rocha, Gifone Aguiar ^a   de Melo, Fabrício Freire ^a   Clementino, Nelma Cristina Diogo ^a   Marino, Marília Campos Abreu ^a   Bozzi, Adriana ^b   Silva, Maria Luiza ^b   Filho, Olindo Assis Martins ^b   Queiroz, Dulciene Maria Magalhães ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Immune thrombocytopenia; Th1 cell; Th17 cell; Th2 cell

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 22P70; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TH17 CELLS; YOUNG ADULT;

EID: 80053646104     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.046417     Document Type: Article

References (22)

1. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost. 2008;99(1):4-13.
2. McMillan R. Antiplatelet antibodies in chronic Immune Thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am. 2009;23(6):1163-75.
3. Semple JW, Milev Y, Cosgrave D, Mody M, Hornstein A, Blanchette V, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T cell-reactivity. Blood. 1996;87(10):4245-54.
4. Zhou B, Zhao H, Yang RC, Han ZC. Multidysfunctional pathophysiology in ITP. Crit Rev Oncol Hematol. 2005;54(2);107-16.
5. Olsson B, Andresson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LMS, et al. T-cell mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123-4
6. Lit LC, Wong CK, Li EK, Tam LS, Lam CW, Lo YM. Elevated gene expression of Th1/Th2 associated transcription factors is correlated with disease activity in patients with systemic lupus erythematosus. J Rheumatol. 2007;34(1):89-96.
7. Panitsas FP, Theodoropoulou M, Kouraklis A, Karakantza, M, Theodorou, GL, Zoumbos NC, et al. Adult chronic idiopathic thrombocytopenic purpura is the manifestation of a type-1 polarized immune response. Blood. 2004;103(7): 2645-7.
8. Guo C, Chu X, Shi Y, He W, Li L, Wang L, et al. Correction of Th1-dominat cytokine profiles by high-dose deamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol. 2007; 27(6):557-62.
9. Stasi R, Cooper N, Del Poeta G, Stipa E, Evangelista ML, Abruzzese E, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008;112(4):1147-50.
10. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123-32.
11. Korn T, Betelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485-517.
12. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, et al. Interleukin 17 acts in synergy with B cellactivating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol. 2009;10(7):778-85.
13. Ma D, Zhu X, Zhao P, Zhao C, Li X, Zhu Y, et al. Profile of Th17 cytokines (IL-17, TGF-β, IL-6) and Th1 cytokine (IFN-γ) in patients with immune thrombocytopenic purpura. Ann Hematol. 2008;87(11):899-904.
14. Guo ZX, Chen ZP, Zheng CL, Jia HR, Ge J, Gu DS, et al. The role of Th17 cells in adult patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 2009;82(6):488-9.
15. Zhang J, Ma D, Zhu X, Qu X, Ji C, Hou M. Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura. Haematologica. 2009; 94(9):1327-8.
16. Zhu X, Ma D, Zhang J, Peng J, Qu X, Ji C, et al. Elevated interleukin-21 correlated to Th17 and Th1 cells in patients with immune thrombocytopenia. J Clin Immunol. 2010;30(2):253-9.
17. Rodeghiero F, Stasi R, Gernsheimes T, Michel M, Provan D, et al. Standardization of terminology, definition and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-93.
18. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-86.
19. Volpe E, Servant N, Zollinger R, Bogiatzi S, Hupé P, Barillot E, et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol. 2008;9(6):650-7.
20. Zhu XJ, Shi Y, Peng J, Guo C, Shan N, Qin P, Ji X, Hou M. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. Blood. 2009;114(26): 5362-7.
21. McMinn JR Jr, Cohen S, Moore J, Lilly S, Parkhurst J, Tarantino MD, et al. Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with Etanercept. Am J Hematol. 2003;73(2):135-40.
22. Rocha AMC, Souza C, Rocha GA, Melo FF, Saraiva IBS, Clementino NCD, Marino MAC, Queiroz DMM. IL1RN VNTR and IL2-330 polymorphic genes are independently associated with chronic Immune Thrombocytopenia. Br J Haematol. 2010; 150(6):679-84